A Study of Viral Response to Triple Therapy in Hepatitis C Virus-Infected Participants With Insulin Resistance Who Failed Dual Therapy (MK-3034-113)

NCT01770223 · clinicaltrials.gov ↗

PHASE4

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Conditions

Hepatitis C

Interventions

DRUG: boceprevir
BIOLOGICAL: PegIFN-2b
DRUG: RBV

Sponsor

Merck Sharp & Dohme LLC